GlassScriptPhysician profile
Pablo F Perez
NPI 1356792675
$12,235.51
in general payments reported to CMS, 2019-2025
29 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,456 · 2022: $3,542 · 2023: $4,328 · 2024: $527 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,237.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,214.55 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,519.48 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,511.56 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Neurocrine Biosciences, INC. | $847.82 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $830.60 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $768.42 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $750.17 | 2021-2025 | Spravato, Invega |
| Corium, LLC | $514.62 | 2022-2024 | Azstarys |
| Neos Therapeutics, LP | $485.12 | 2021-2023 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $347.85 | 2022-2023 | Gralise |
| E.R. Squibb & Sons, L.L.C. | $316.72 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $247.33 | 2022-2024 | Auvelity, Sunosi |
| Eisai INC. | $245.67 | 2021 | |
| Noven Therapeutics, LLC | $195.59 | 2023-2024 | Xelstrym, Secuado |
| Avanir Pharmaceuticals, INC. | $194.71 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $187.01 | 2021-2023 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $183.46 | 2021-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $180.20 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $134.62 | 2022-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $99.57 | 2021-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $82.01 | 2021-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $80.86 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $73.28 | 2021 | |
| Harmony Biosciences LLC | $66.32 | 2022 | |
| Tris Pharma INC | $57.87 | 2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $40.98 | 2022 | |
| Adlon Therapeutics L.P. | $24.31 | 2021 | |
| Aytu Biopharma, INC. | $22.75 | 2021 | |
| Merck Sharp & Dohme LLC | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.